Jo K Perry

Summary

Affiliation: University of Auckland
Country: New Zealand

Publications

  1. doi request reprint Growth hormone and cancer: an update on progress
    Jo K Perry
    Liggins Institute, University of Auckland, Auckland, New Zealand
    Curr Opin Endocrinol Diabetes Obes 20:307-13. 2013
  2. ncbi request reprint Artemin-stimulated progression of human non-small cell lung carcinoma is mediated by BCL2
    Jian Zhong Tang
    Liggins Institute, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand
    Mol Cancer Ther 9:1697-708. 2010
  3. doi request reprint STAT3alpha is oncogenic for endometrial carcinoma cells and mediates the oncogenic effects of autocrine human growth hormone
    Jian Zhong Tang
    Liggins Institute, Faculty of Medical and Health Sciences, University of Auckland, Auckland 1142, New Zealand
    Endocrinology 151:4133-45. 2010
  4. doi request reprint Signal transducer and activator of transcription (STAT)-5A and STAT5B differentially regulate human mammary carcinoma cell behavior
    Jian Zhong Tang
    The Liggins Institute, University of Auckland, 2 6 Park Avenue, Private Bag 92019, Auckland 1023, New Zealand
    Endocrinology 151:43-55. 2010
  5. doi request reprint PAX5alpha enhances the epithelial behavior of human mammary carcinoma cells
    Laurent J P Vidal
    The Liggins Institute, The University of Auckland, Auckland, New Zealand
    Mol Cancer Res 8:444-56. 2010
  6. doi request reprint Artemin stimulates oncogenicity and invasiveness of human endometrial carcinoma cells
    Vijay Pandey
    The Liggins Institute, University of Auckland, 2 6 Park Avenue, Private Bag 92019 Auckland, New Zealand
    Endocrinology 151:909-20. 2010
  7. doi request reprint Autocrine human GH promotes radioresistance in mammary and endometrial carcinoma cells
    Nicola M Bougen
    The Liggins Institute, University of Auckland, Auckland, New Zealand
    Endocr Relat Cancer 19:625-44. 2012
  8. pmc Trefoil factor 3 is oncogenic and mediates anti-estrogen resistance in human mammary carcinoma
    Nagarajan Kannan
    Liggins Institute, University of Auckland, Auckland, New Zealand
    Neoplasia 12:1041-53. 2010
  9. doi request reprint Trefoil factor-1 (TFF1) enhances oncogenicity of mammary carcinoma cells
    Naeem Amiry
    The Liggins Institute, University of Auckland, Private Bag 92019, Auckland, New Zealand
    Endocrinology 150:4473-83. 2009
  10. pmc Autocrine human growth hormone stimulates oncogenicity of endometrial carcinoma cells
    Vijay Pandey
    Liggins Institute and National Research Centre for Growth and Development, University of Auckland, 2 6 Park Avenue, Private Bag 92019 Auckland, New Zealand
    Endocrinology 149:3909-19. 2008

Collaborators

Detail Information

Publications18

  1. doi request reprint Growth hormone and cancer: an update on progress
    Jo K Perry
    Liggins Institute, University of Auckland, Auckland, New Zealand
    Curr Opin Endocrinol Diabetes Obes 20:307-13. 2013
    ..Conversely, increased expression levels of GH and the GH receptor (GHR) are detectable in a variety of different human cancers. Here we discuss recent literature contributing to our understanding of the field...
  2. ncbi request reprint Artemin-stimulated progression of human non-small cell lung carcinoma is mediated by BCL2
    Jian Zhong Tang
    Liggins Institute, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand
    Mol Cancer Ther 9:1697-708. 2010
    ..ARTN therefore mediates progression of NSCLC and may be a potential therapeutic target for NSCLC...
  3. doi request reprint STAT3alpha is oncogenic for endometrial carcinoma cells and mediates the oncogenic effects of autocrine human growth hormone
    Jian Zhong Tang
    Liggins Institute, Faculty of Medical and Health Sciences, University of Auckland, Auckland 1142, New Zealand
    Endocrinology 151:4133-45. 2010
    ..STAT3alpha may therefore be a common mediator of oncogenic signaling pathways stimulating progression of EC...
  4. doi request reprint Signal transducer and activator of transcription (STAT)-5A and STAT5B differentially regulate human mammary carcinoma cell behavior
    Jian Zhong Tang
    The Liggins Institute, University of Auckland, 2 6 Park Avenue, Private Bag 92019, Auckland 1023, New Zealand
    Endocrinology 151:43-55. 2010
    ..Xenograft studies provided data concordant with the in vitro effects of the two STAT5 isoforms. We therefore demonstrate that STAT5A and STAT5B differentially regulate behavior of human mammary carcinoma cells...
  5. doi request reprint PAX5alpha enhances the epithelial behavior of human mammary carcinoma cells
    Laurent J P Vidal
    The Liggins Institute, The University of Auckland, Auckland, New Zealand
    Mol Cancer Res 8:444-56. 2010
    ..These studies show that PAX5alpha enhances the epithelial characteristics of mammary carcinoma cells, reminiscent of mesenchymal to epithelial transition...
  6. doi request reprint Artemin stimulates oncogenicity and invasiveness of human endometrial carcinoma cells
    Vijay Pandey
    The Liggins Institute, University of Auckland, 2 6 Park Avenue, Private Bag 92019 Auckland, New Zealand
    Endocrinology 151:909-20. 2010
    ..Thus, inhibition of ARTN may be considered as a potential therapeutic strategy to retard progression of EC...
  7. doi request reprint Autocrine human GH promotes radioresistance in mammary and endometrial carcinoma cells
    Nicola M Bougen
    The Liggins Institute, University of Auckland, Auckland, New Zealand
    Endocr Relat Cancer 19:625-44. 2012
    ..Functional antagonism of hGH, used in conjunction with radiotherapy, may therefore enhance treatment efficacy and improve the prognosis of patients with breast and endometrial cancer...
  8. pmc Trefoil factor 3 is oncogenic and mediates anti-estrogen resistance in human mammary carcinoma
    Nagarajan Kannan
    Liggins Institute, University of Auckland, Auckland, New Zealand
    Neoplasia 12:1041-53. 2010
    ..Functional antagonism of TFF3 therefore warrants consideration as a novel therapeutic strategy for mammary carcinoma...
  9. doi request reprint Trefoil factor-1 (TFF1) enhances oncogenicity of mammary carcinoma cells
    Naeem Amiry
    The Liggins Institute, University of Auckland, Private Bag 92019, Auckland, New Zealand
    Endocrinology 150:4473-83. 2009
    ..We have therefore demonstrated that TFF1 possesses oncogenic functions in mammary carcinoma cells. Functional antagonism of TFF1 can therefore be considered as a novel therapeutic strategy for mammary carcinoma...
  10. pmc Autocrine human growth hormone stimulates oncogenicity of endometrial carcinoma cells
    Vijay Pandey
    Liggins Institute and National Research Centre for Growth and Development, University of Auckland, 2 6 Park Avenue, Private Bag 92019 Auckland, New Zealand
    Endocrinology 149:3909-19. 2008
    ..These studies demonstrate a functional role for autocrine hGH in the development and progression of endometrial carcinoma and indicate potential therapeutic relevance of hGH antagonism in the treatment of endometrial carcinoma...
  11. pmc The contribution of growth hormone to mammary neoplasia
    Jo K Perry
    The Liggins Institute, University of Auckland, 2 6 Park Avenue, Private Bag 92019, Auckland, New Zealand
    J Mammary Gland Biol Neoplasia 13:131-45. 2008
    ..This review will highlight recent evidence linking GH and mammary carcinoma and discuss GH-antagonism as a potential therapeutic approach for treatment of breast cancer...
  12. ncbi request reprint Autocrine human growth hormone promotes tumor angiogenesis in mammary carcinoma
    Severine E Brunet-Dunand
    Liggins Institute, University of Auckland, Private Bag, Auckland, New Zealand
    Endocrinology 150:1341-52. 2009
    ..Consideration of hGH antagonism to inhibit angiogenic processes in mammary carcinoma is therefore warranted...
  13. doi request reprint The prolactin receptor mediates HOXA1-stimulated oncogenicity in mammary carcinoma cells
    Lin Hou
    Liggins Institute, University of Auckland, Auckland 1023, New Zealand
    Int J Oncol 41:2285-95. 2012
    ..Thus, the PRLR is one mediator of HOXA1‑stimulated oncogenicity in mammary carcinoma cells...
  14. doi request reprint Autocrine human growth hormone reduces mammary and endometrial carcinoma cell sensitivity to mitomycin C
    Nicola M Bougen
    Liggins Institute, University of Auckland, Auckland 1023, New Zealand
    Oncol Rep 26:487-93. 2011
    ..Thus, autocrine hGH promotes mammary and endometrial carcinoma cell resistance to MMC. These studies indicate a potential role for antagonism of autocrine hGH in chemoresistant breast cancer...
  15. doi request reprint Transcriptional activation of signal transducer and activator of transcription (STAT) 3 and STAT5B partially mediate homeobox A1-stimulated oncogenic transformation of the immortalized human mammary epithelial cell
    Kumarasamypet M Mohankumar
    The Liggins Institute and National Research Centre for Growth and Development, University of Auckland, Auckland, New Zealand
    Endocrinology 149:2219-29. 2008
    ..These results suggest that HOXA1 partially mediates oncogenic transformation of the immortalized human mammary epithelial cell through modulation of the STAT3 and STAT5B pathways...
  16. ncbi request reprint The oncogenic potential of growth hormone
    Jo K Perry
    The Liggins Institute and the National Research Centre for Growth and Development, University of Auckland, 2 6 Park Avenue, Grafton, Private Bag 92019, Auckland 1023, New Zealand
    Growth Horm IGF Res 16:277-89. 2006
    ..Here we review the accumulating evidence implicating growth hormone in the development and progression of cancer and describe what is known of the mechanisms utilised by this hormone in neoplastic transformation...
  17. ncbi request reprint SHON is a novel estrogen-regulated oncogene in mammary carcinoma that predicts patient response to endocrine therapy
    Yewon Jung
    Authors Affiliations Liggins Institute, University of Auckland, Auckland, New Zealand Department of Clinical Oncology Department of Histopathology, School of Molecular Medical Sciences, University of Nottingham and Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom The Key Laboratory of Molecular Epigenetics of Ministry of Education, Northeast Normal University The Institute of Genetics and Cytology, Northeast Normal University, Changchun Institute of Genetics and Developmental Biology, Chinese Academy of Sciences, Beijing Hefei National Laboratory for Physical Sciences at Microscale and School of Life Sciences, University of Science and Technology of China Department of Pathology, Anhui Medical University, Hefei, China Cancer Science Institute of Singapore, and Department of Pharmacology, National University of Singapore and National Cancer Institute of Singapore, National University Health System, Singapore
    Cancer Res 73:6951-62. 2013
    ....
  18. ncbi request reprint Are trefoil factors oncogenic?
    Jo K Perry
    Liggins Institute, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand
    Trends Endocrinol Metab 19:74-81. 2008
    ..This review will summarize the current evidence for the involvement of TFFs in human cancer...